4//SEC Filing
DIACRIN INC /DE/ 4
Accession 0001104659-03-019532
CIK 0000887137operating
Filed
Aug 24, 8:00 PM ET
Accepted
Aug 25, 4:13 PM ET
Size
17.1 KB
Accession
0001104659-03-019532
Insider Transaction Report
Form 4
DIACRIN INC /DE/DCRN
RUCH JOSHUA
Director
Transactions
- Disposition to Issuer
Common Stock
2003-08-21−166,700 - Disposition to Issuer
Employee stock option (right to buy)
2003-08-21−20,000→ 0 totalExercise: $7.13Exp: 2008-06-15→ Common Stock (20,000 underlying) - Disposition to Issuer
Employee stock option (right to buy)
2003-08-21−6,000→ 0 totalExercise: $5.13Exp: 2009-09-13→ Common Stock (6,000 underlying) - Disposition to Issuer
Common Stock
2003-08-21−1,592,887(indirect: By Trust) - Disposition to Issuer
Employee stock option (right to buy)
2003-08-21−10,000→ 0 totalExercise: $1.62Exp: 2012-06-17→ Common Stock (10,000 underlying)
Footnotes (8)
- [F1]Disposed of pursuant to a merger agreement between the issuer and GenVec, Inc. (the "merger agreement") in exchange for 254,917 shares of GenVec common stock having an aggregate value of $588,858 on the effective date of the merger.
- [F2]Disposed of pursuant to the merger agreement in exchange for 2,435,842 shares of GenVec common stock having an aggregate value of $5,626,795 on the effective date of the merger.
- [F3]The reporting person is the Chairman and Chief Executive Officer of Rho Capital Partners, Inc., which exerts voting and investment control over shares owned by Rho Management Trust II ("RMT II"), and, as such, the reporting person may be deemed the beneficial owner of the shares held by RMT II.
- [F4]This stock option, which is fully vested and immediately exercisable, was assumed by GenVec in connection with the merger and replaced with an option to purchase 30,584 shares of GenVec common stock at an exercise price of $4.66 per share.
- [F5]This stock option, which provides for vesting in four equal annual installments beginning on September 13, 2000, was assumed by GenVec in connection with the merger and replaced with an option to purchase 9,175 shares of GenVec common stock at an exercise price of $3.36 per share.
- [F6]This stock option, which provides for vesting in four equal annual installments beginning on June 19, 2001, was assumed by GenVec in connection with the merger and replaced with an option to purchase 9,175 shares of GenVec common stock at an exercise price of $5.15 per share.
- [F7]This stock option, which provides for vesting in four equal annual installments beginning on June 11, 2002, was assumed by GenVec in connection with the merger and replaced with an option to purchase 9,175 shares of GenVec common stock at an exercise price of $1.31 per share.
- [F8]This stock option, which provides for vesting in four equal annual installments beginning on June 17, 2003, was assumed by GenVec in connection with the merger and replaced with an option to purchase 15,292 shares of GenVec common stock at an exercise price of $1.06 per share.
Documents
Issuer
DIACRIN INC /DE/
CIK 0000887137
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000887137
Filing Metadata
- Form type
- 4
- Filed
- Aug 24, 8:00 PM ET
- Accepted
- Aug 25, 4:13 PM ET
- Size
- 17.1 KB